Monthly Maintenance Items for FormsNet3

Each month the FormsNet3^SM team makes updates to validations, question enabling/disabling and form generation.
The monthly maintenance updates are tentatively scheduled for the 4th Friday of the month.

May 2023 (released May 19, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2450r7 / F2100r4-8	Q16 (F2450) / Q18 (F2100)	Validation (Add)	“Not Applicable” available as answer option	“Not Applicable” will NOT be allowed to be reported for 6M, 1Y, and 2Y reporting periods	Consistency with ANC data capture update in April
F4100r8/9	Q180 and 187 (r8) / Q153 and 160 (r9)	Validation (Modify)	If current treatment path is equal to 2, questions must be answered	Disabled for combined follow-up when 2nd event is HCT	Burden reduction
F2450r7 / 2011r8	Q67 (F2450) / Q65 (F2100)		Answer option reads “PCR (includes quantitative, real time, and fluorescent multiplex)”	Option PCR changed to “Single nucleotide polymorphisms (SNPs) (includes quantitative PCR, real-time PCR, sequencing, other)”	Updated for more inclusive data capture

April 2023 (released April 21, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2400 r10	Q135	Validation (Add)	No option available to report “none”	“None” available as answer option	Allows “None” as answer without requiring override error code
F2400 r10	Q21	Validation (Modify)	If recipient is participating in a clinical trial AND Study Sponsor = Other Sponsor OR Study ID = BMT CTN 1903, then NCT ID must be answered	NCT ID required for all clinical trials	All clinical trials will report NCT ID. Exception: RCI BMT studies with no NCT ID – reporting NCT ID will be optional in this case

February 2023 (released February 24, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2600 r5 / r6		Validation (Modify)	If HCT = allo unrelated AND product type is BM or PBSC, then GRID must be answered	If HCT = allo unrelated AND product type is BM or PBSC OR HCT = allo related and NMDP product, then GRID must be answered	Include allo related NMDP product infusions

January 2023 (released January 27, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r8	Q136	Validation (Modify)	Disabled for the 100 day visit	Enabled for both acute and chronic GVHD	Allows capture of GVHD that persists across infusions

December 2022 (released December 9, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2013 r3	Q3	Validation (Modify)	If subsequent transplant or cell therapy, then Q3 is disabled	Q3 must be answered for every transplant and cell therapy (regardless if subsequent or first)	Provides disease status at latest assessment
F2900 r5		Events & Actions	If primary cause of death = COVID-19 OR contributing cause of death contains COVID-19, then a F2149 comes due	As of November 2022, F2149 will not come due for TED track (except those enrolled in CTN 2101 study)	F2149 is no longer collected for TED track
F2000 r6	Q80	Validation (Modify)	No decimal place available when entering dosing weight	One decimal place available when entering dosing weight	Exact dosing weight necessary to capture data accurately, especially in pediatric patients

November 2022 (released November 18, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2450 r7		Events & Actions	If Q49 Did the recipient develop COVID-19 since the date of last report = yes, then F2149 comes due for both TED and CRF tracks	F2149 will only come due for CRF track and the on demand ability for F2149 on TED track is removed	F2149 will only be requested for CRF track

October 2022 (released October 21, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2400 r9	Q91	Events & Actions	5 instances allowed for COVID vaccine	8 instances allowed for COVID vaccine	Matches the most recent forms
F2400 r9	Q6	Validation (Modify)	If country of primary residence = United States, then zip/postal code must be answered	If country of primary residence = United States OR US territories, then zip/postal code must be answered	All US territories must have zip/postal codes reported
F2400 r9	Q6	Validation (Add)	N/A	If Q6 country = any United States or US territory, then Q3 Ethnicity must not = N/A	Ethnicity must be entered for all states and territories
F2199 r1	Q9	Validation (Modify)	If CBC result available is EQUAL TO lymphocytes, then lymphocyte value must be answered	If CBC result available CONTAINS lymphocytes, then lymphocyte value must be answered	​If a CBC result has a lymphocyte value, then the value must be reported
F2400 r10	Q20	Validation (Modify)	If study sponsor = any (USIDNET, COG, PedAL), then subject ID must be answered	If study sponsor = PedAL, then subject ID must be answered. If study sponsor = any other, then subject ID is optional	Subject ID only needs to be answered if the study sponsor is PedAL

June 2022 (released June 24, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2028 r3	Q78, Q94	Validation (Modify)	Currently questions 78 and 94 must be answered, regardless of primary disease	If Primary Disease = MDS, ALL, or AML, then Q78 and Q94 will be disabled	This information is already captured for these primary diseases, therefore Q78 and Q94 do not need to be answered
F2450 r5 & r6	Q50	Validation (Modify)	Q50 MUST be answered	Q50 is optional if date of actual contact with the patient is before March 30, 2020	Pre-covid timeframe

May 2022 (released May 20, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2400 r9 / F2402 r6		Events & Actions	Currently NMDP related donors only get 2006 forms on TED track when repository consent = yes	All NMDP related products will receive the 2006 form, regardless of repository consent	All NMDP related products should receive the 2006 form
F2100 r7	Q311	Smart Navigation (Modify)	​If Q311 = No, then go to Q315	If Q311 = No, then go to Q312	Date of discharge needs to be reported when procedure was planned to be inpatient.
F2016 r5	Q177	Validation (Add)	N/A	Q177 must not be equal to Not Applicable	Not a real scenario
F2116 r5	Q160/Q187/Q208	Validation (Modify)	If Q155 = Yes, then Q160 must be answered	If Q158 is = to Known or Unknown, then Q160 must be answered	​Dose should be disabled until the radiation is stopped. If the patient receives therapy across multiple reporting periods, report the total dose all at once after the radiation is stopped

April 2022 (released April 22, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2814 r4	Q2	Validation (New)	None	Q2 Event date: MUST BE NOT EQUAL TO Core: Patient event dates OR Q2 Event date: MUST BE EQUAL TO Core: HSCT Date	The CIBMTR is preventing a F2814 being completed for an event already created
F2400 r9	Q23	Validation (Modify)	​If Q18 = yes AND Q49 = yes, then Q23 is optional	If Q18 = yes AND Genetically Modified AND Q19 = Other sponsor OR Q21 = BMT CTN 1903 – HIV T Cell, then Q23 must be answered
F2400 r9 / F2402 r6		Events & Actions	None	If Form Track = CRF AND F2402 Q451 = Transfusion dependent thalassemia, then Forms F2058 and F2158s will generate	New disease specific form released in the Spring 2022 release
F2402 r6	Q433	Validation (Modify)	If Q427 = yes, then Q433 must be answered	If Q428 = yes, then Q433 must be answered	Validation was updated to be on the Q428, rather than Q427
F2450 r6		Events & Action	If Visit ID = 100 Days and Q48 = Yes, then generate F2553 100 Days	If Visit ID = 100 Days and Q48 = Yes, then generate F2553 100 Days AND enroll in study SP16-02	Study enrollment is open
F2100 r6		Events & Action	If Visit ID = 100 Days and Q498 = Yes, then generate F2553 100 Days	If Visit ID = 100 Days and Q498 = Yes, then generate F2553 100 Days AND enroll in study SP16-02	Study enrollment is open
F4100 r8	Q27	Validation (Modify)	​If Q25 = yes, then Q27 must be answered	If Q1 = (Axicabtagene, Brexucabtagene, Ciltacabtegene, Idecabtegene, Lisocabtagene, Tisagenlecleucel), then Q27 must be answered
F2116 r5	Q228	Validation (Modify)	​If Q1 = (AMYL, MGRS, OTH_PCL ) OR Q2 = (AMYL, MGRS), then Q228 must be answered	​​Remove criteria for AMYL, MGRS. These questions should be “must be answered” for all.
F2116 r5	Q230	Validation (Modify)	If Q1 = (AMYL, MGRS) OR Q2 = (AMYL, MGRS), then Q230 must be answered	​​ Remove criteria for AMYL, MGRS. These questions should be “must be answered” for all
F2116 r5	Q232	Validation (Modify)	If Q1 = (AMYL, MGRS) OR Q2 = (AMYL, MGRS), then Q232 must be answered	​​Remove criteria for AMYL, MGRS. These questions should be “must be answered” for all

March 2022 (released March 25, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F4100 r8	Q95	Floating Text (Modify)	Q95 floating text currently states: > 100.4 F or > 38 C	Q95 floating text modified to ≥ 100.4 F or ≥ 38 C

February 2022 (released Feb 25, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2010 r4	Q83	Validation (Modify)	Q83 Range for percent disease detected (in blood) must be between 0.001 and 4	Q83 Range for percent disease detected (in blood) must be between 0.001 and 99.999	Range is updated to be consistent with F2111
F2016 r5	Q237	Validation (Modify)	If Q236 = Abnormalities identified, then Q237 must be answered	disabled question for all	ISCN string is not currently collected
F2016 r5	Q243	Validation (Modify)	If Q242 = Abnormalities identified, then Q243 must be answered	disabled question for all	ISCN string is not currently collected
F4100 r8	Q4	Validation (Modify)	If the F4000 Q54 = Outpatient and F4100 Visit is 100 days, then F4100 Q4 must be answered	If F4000 Q54 = Outpatient, F4100 Visit is 100 days and Current event is Cellular Therapy, then Q4 must be answered	Updated so only Cell Therapy events have to answer this question. Previous validation was requiring Q4 to be answered for HCT events that were a part of combined follow-up
F4100 r8	Q27	Validation (Modify)	Q27 must be answered	If Q25 = Yes, then Q27 must be answered

January 2022 (released Jan 28, 2022)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2400 r9	Q17	Validation (New)	None	Q17 “Research Sample Recipient ID” cannot be equal to Q10 “RID”	IDs cannot be the same
F2400 r9	Q76	Validation (New)	None	Q76 “Research Sample Donor ID” cannot be equal to Q10 “RID”	IDs cannot be the same
F2400 r9 / F2402 r6	N/A	Events & Actions	If form track = CRF and (F2402 Q488 = NEUTD, GST2, HPST2 and Patient is alive), then F2056/2156 generates	If form track = CRF and (F2402 Q488 = Chediak-Higashi syndrome, Griscelli syndrome type 2, Hermansky-Pudlak syndrome type 2, Other pigmentary dilution disorder and Patient is alive), then F2056/2156 generates	Added ‘Other pigmentary dilution disorder’ to generate the disease specific forms
F2402 r6	Q449	Validation (Modify)	If Q2 = IBMFS, then Q449 must be answered (no override allowed)	If Q2 = IMBFS, then Q449 must be answered	An override can be used on Q449, as not all subtypes (e.g. other, specify) are listed. Centers can leave an override and specify the subtype in the override comment.
F2014 r4	Q152	Validation (Modify)	If (Q151 = CR, NR_SD, Prog from HI, Rel from CR) or (Q152 = HI-P, HI-N) or (Q153 = LTB, HTB), then Q154 must be answered	If (Q151 = CR, NR_SD, Prog from HI, Rel from CR) or (Q152 contains either HI-P or HI-N) or (Q153 = LTB, HTB), then Q154 must be answered	Q152 is a ‘check all that apply’; validation was updated to allow multiple options
F2057 r1	Q208	Validation (Modify)	Q208 date must be between the dates reported in Q186 and Q208	Q208 date must be between Q184 and Event date
F2057 r1	Q210	Validation (Modify)	Q210 date must be between the dates reported in Q186 and Q208	Q210 date must be between Q184 and Event date
F2100 r7	Q254	Validation (New)	None	If Q254 contains (BLA, TRANSBRONCH_BIOP, OPEN_VATS, AUTOPSY, OTHR), then Q254 cannot contain No diagnostic tests done	If a diagnostic method is selected, then it is not logical to also select ‘No diagnostic tests done’
F2116 r5	Q94	Validation (Modify)	If 91 = HEP_RES, NR_SD, PD, then Q94 must be answered	If 92 = Known, Unknown, then Q94 must be answered	Updated to match the flow of the form and manual
F2116 r5	Q95	Validation (Modify)	If 91 = HEP_RES, NR_SD, PD, then Q95 must be answered	If Q92 = Known, Unknown, then Q95 must be answered	Updated to match the flow of the form and manual
F2116 r5	Q218	Validation (Modify)	If Q216 = Known, then Q218 must be answered	If Q217 = any M-spike type (excluding ‘No bands present’), then Q218 must be answered
F2116 r5	Q219	Validation (Modify)	If Q216 = Known, then Q219 must be answered	If Q217 = any M-spike type (excluding ‘No bands present’), then Q219 must be answered

Copyright © 2004-2019 The Medical College of Wisconsin, Inc. and the National Marrow Donor Program. All Rights Reserved.
CIBMTR®(Center for International Blood and Marrow Transplant Research®) is a research collaboration between the National Marrow Donor Program®/Be The Match® and the Medical College of Wisconsin